As the first not-for-profit publisher to commit to this approach, the Company’s three hybrid journals – Development, Journal of Cell Science and Journal of Experimental Biology – have chosen the ‘transformative’ route towards Open Access.
The Company of Biologists has offered Open Access publishing options since 2004 and two of its five journals are already fully Open Access. The Transformative Journal strategy signals more clearly the journals’ commitment to move towards full Open Access, while a transition period allows the Company to provide publishing options that support all authors through this change in the publishing landscape.
Transformative Journals proactively champion Open Access publishing and have Open Access growth targets. Over the 2021-2024 transition period, the three journals aim to grow the proportion of Open Access research content by 5% year-on-year. When Open Access research content reaches 75%, the journals will flip to full Open Access. As The Company of Biologists transitions towards Open Access, authors will still have the same three routes to publication:
- Free publication (not Open Access)
- Gold Open Access (author pays)
- Free Open Access publishing for corresponding authors from institutions taking up our Read & Publish agreements
“We believe Open Access is the direction of travel and we are excited about this next step on our Open Access journey. This is about more than just becoming Plan S compliant,” said Claire Moulton, Publisher at The Company of Biologists. “The Transformative Journal approach helps us balance two key priorities – making research accessible to everyone and our support of the whole author community. Our Open Access growth targets will be challenging. We plan to be transparent about our progress so there are no big surprises along the way.”
Open Access growth will require real changes in the marketplace, such as funder mandates (including financial support for Gold Open Access) and more libraries/consortia taking up Read & Publish agreements to enable authors to publish free Open Access articles in the journals. These changes may be even more challenging given the financial difficulties expected in the university sector post-COVID-19. To maximise the chances of success, The Company of Biologists will be working closely with its stakeholders throughout this exciting journey towards full Open Access.
Robert Kiley, Head of Open Research at Wellcome, commented: “I am delighted that The Company of Biologists is fully committed to transitioning its journals to full Open Access – as evidenced by the Read and Publish arrangements developed last year and the announcement today that their three subscription journals will become Transformative Journals, from January 2021. We welcome the commitment to transition to full Open Access, to offset subscription income from payments for publishing services and to work to increase the share of OA content, year-on-year. I hope other journals follow the lead set by The Company of Biologists.”
Further information available at: http://www.
About The Company of Biologists
The Company of Biologists is a not-for-profit publishing organisation dedicated to supporting and inspiring the biological community. The Company publishes five specialist peer-reviewed journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open. It offers further support to the biological community by facilitating scientific meetings, providing travel grants for researchers and supporting research societies.
Jitske de Vries